Compare NMM & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMM | GENB |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2007 | N/A |
| Metric | NMM | GENB |
|---|---|---|
| Price | $81.35 | $14.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $85.00 | $23.20 |
| AVG Volume (30 Days) | 93.1K | ★ 578.3K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $3.66 | $16.58 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.66 | $11.00 |
| 52 Week High | $80.97 | $18.18 |
| Indicator | NMM | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 46.64 |
| Support Level | $69.21 | $11.73 |
| Resistance Level | $80.69 | $14.82 |
| Average True Range (ATR) | 2.50 | 0.78 |
| MACD | 0.53 | -0.07 |
| Stochastic Oscillator | 79.97 | 64.59 |
Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.